Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Health Care Fund Neal Kaufman | “Biotechnology company argenx SE is best known for developing Vygart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose after a period of prior weakness, which may have been partly driven by the retirement of longtime CEO Tim Van Hauwermeiren in early 2026. We view the transition to Karen Massey, who previously led the company's operations, as largely non-disruptive and believe she is well positioned to continue executing the company's strategy. Shares also benefited from optimism ahead of several clinical readouts, including data from studies of Vyvgart in immune-mediated necrotizing myopathy and dermatomyositis, expected in the third quarter of 2026, as well as empasibrupart in multifocal motor neuropathy, expected in the fourth quarter of 2026. Vyvgart continues to launch well in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, where we believe it has established itself as an important treatment option. We expect Vyvgart to demonstrate efficacy across an expanding range of autoantibody-driven autoimmune conditions over time and remain encouraged by argenx's pipeline progress.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Baron Health Care Fund Neal Kaufman | “Argenx SE is best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose as Vyvgart sales meaningfully exceeded investor expectations. Our conversations with management and neurologists continue to reinforce Vyvgart's value as an important treatment option with strong long-term growth potential. The drug continues to launch well in generalized myasthenia gravis, and its launch in chronic inflammatory demyelinating polyneuropathy is off to a strong start. Over time, we expect Vyvgart to demonstrate efficacy across an expanding range of autoantibody-driven autoimmune conditions, supported by pipeline progress and upcoming Phase 3 readouts. BSD Analysis: argenx has already done what most biotechs only promise: turn novel science into a real commercial franchise. Its antibody platform has produced drugs that meaningfully change outcomes in rare autoimmune diseases. The lead product is expanding into multiple indications, turning niche success into a platform story. Pricing power is strong because alternatives are limited and efficacy is clear. The pipeline behind the flagship is credible, not speculative. Execution has been disciplined, avoiding the usual biotech sprawl. Cash flow visibility is improving, which changes how risk should be viewed. This is no longer a “hope stock.” It's a high-quality growth biotech with momentum and substance.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Artisan Mid Cap Fund Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay Warner | “Argenx's autoimmune therapy VYVGART® continues to deliver strong growth, driven by a subcutaneous formulation launch that allows self-administration. The company is expanding indications across multiple autoimmune disorders and is positioned for a durable, multibillion-dollar profit cycle based on repeatable innovation and global commercial execution. BSD Analysis: argenx remains one of the most compelling high-growth biotech names, with Vyvgart continuing to deliver strong uptake across generalized myasthenia gravis and expansion opportunities in multiple autoimmune indications. Clinical execution remains best-in-class, and early subcutaneous data position argenx for sustained global adoption. The balance sheet is strong, giving the company room to invest aggressively in label expansions and pipeline development. While valuation reflects high expectations, argenx's clinical results and commercial ramp justify the premium. With a large autoimmune TAM and a differentiated mechanism, argenx remains a top-tier biotech compounder.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Baron Health Care Fund Neal Kaufman | “Argenx detracted in Q2 following weaker-than-expected demand for Vyvgart, its flagship therapy for generalized myasthenia gravis. Management cited slower new patient starts and competitive pressures. The company lowered full-year guidance and noted rising operating expenses tied to commercialization and pipeline investments. Investors reacted negatively to the reduced visibility and uncertain trajectory for Vyvgart. BSD Analysis: argenx is one of biotech's modern success stories — an immunology pure-play turning antibody innovation into real commercial traction. Vyvgart is scaling globally and expanding across multiple indications, with subcutaneous and chronic-dosing opportunities building a franchise worth far more than the market credits. The pipeline is deep, the tech platform is validated, and execution has been stellar. argenx is a high-quality biotech that behaves like a future megacap.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
